Our molecular mechanism study revealed that USP19 has a role as a co-repressor in the transcriptional repression of RAR via the stabilization of CORO2A by its DUB activity, and suggests the possibility that USP19 may be a potent target for anti-cancer and metabolic diseases. Here, CORO2A is linked to metabolic disease.